Author Archives: Mari Serebrov

An end to Charlotte’s web?

In the annals of popular literature, TV shows and movie scripts, only a handful of pigs have achieved mega stardom: Napoleon, who took over a farm and assassinated his political rivals; Arnold, who epitomized the couch potato at Green Acres;…

Share

Building a wall to keep companies in

They may not realize it, but many Americans woke up this morning with their retirement portfolio worth less than it was a week ago. And it could be worth less tomorrow and even a year or a decade from now…

Share

Ignoring the science for a bigger box of crayons

Once upon a time in the days before enlightenment, we tried to use science to develop our drugs. Believe it or not, researchers actually had to come up with a hypothesis of how a drug might work, what disease it…

Share

No joy in Bio-ville

Whether naughty or nice in 2015, Drugmakers received not what they wanted And not what they needed, For the biggest “must-haves” on their wish list Went mostly unheeded.   At the top of that list, and repeated quite often, Was…

Share

An inconvenient truth

Too often, drugmakers confuse convenience with quality of life, investing untold R&D resources in devising longer-acting formulations and then calling it “innovation.” The only innovation is in how it fends off competition by extending their patent protection. Such “advances” ignore…

Share

Precision medicine in the real world

In a perfect world, doctors would have the diagnostics to determine the right treatment for each patient at the right dose and the right time. It would be called precision medicine. In our world, researchers, doctors and patients are teased…

Share

Better Rx needed to treat drugmakers’ PR malady

Biopharma has a bad PR disease. The diagnosis is pretium offensus, otherwise known as “sticker shock.” The infectious condition has two causes: enormous, inexplicable, overnight price hikes and six-figure drug prices that spread from headlines to become a viral meme…

Share

Lessons learned from You-Know-Who

Duchesnay Inc.’s 15-minutes of fame for its morning sickness drug arguably turned into a few hours’ worth by time the drugmaker complied with an FDA warning letter demanding a corrective ad to offset the omission of risk information in paid…

Share

The next episode of the American horror story

You’ve likely heard the terrified screams induced by the cost of pricey cancer drugs, Gilead Sciences Inc.’s twin hepatitis C therapies and Vertex’s cystic fibrosis breakthroughs. And you may have been rattled by the nightmarish predictions about how a new…

Share

You’ve come a long way, baby, but still a long way to go

Patients have come a long way to get a say in the drug development and approval process. But there’s still some ground to cover if they’re going to move from the passive subject role to a 50-50 partnership that reminds…

Share